Technical Data
L3180-01E
Livin (Baculoviral IAP Repeat Containing Protein 7, BIRC7, Kidney Inhibitor of Apoptosis Protein, KIAP, Livin Inhibitor of Apotosis, Melanoma Inhibitor of Apoptosis Protein, ML-IAP, RING Finger Protein 50, RNF50)
Description:
Livin is a member of the family of inhibitor of apoptosis proteins (IAP) and contains a single copy of a baculovirus IAP repeat (BIR) as well as a RING-type zinc finger domain (1,2). Resistance towards apoptosis is a hallmark of cancer cells and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis (3). IAP proteins inhibit apoptosis by binding to and inhibiting caspases through their BIR domain(s). Some IAP members, like Livin, also have a RING-type finger motif at their carboxyl-terminal which may enhance anti-apoptotic activity. Many RING finger-containing IAPs possess E3 ubiquitin ligase activity and it has been shown that Livin acts as an E3 ubiquitin ligase for targeting the degradation of Smac/DIABLO. Degradation of Smac/DIABLO is thought to be a mechanism to enhance Livin anti-apoptotic activity, thereby promoting cell survival. There is accumulating evidence that Livin plays a significant role in a spectrum of tumor types and it is thought that Livin may have potential as a diagnostic and prognostic tumor marker. Livin is expressed at low levels in adult tissues, and relatively higher levels in developmental tissues and in many cancer cells. Certain cancer patients develop autoantibodies against Livin and in a number of cancers, Livin is detected only in the tumors but not, or to substantially lower levels, in the corresponding normal adjacent tissue.

Applications:
Suitable for use in Western Blot, Immunoprecipitation and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000-1:2000 Because Livin has been shown to undergo proteolytic cleavage during apoptosis, the molecular weight of Livin observed may vary depending on the presence or absence of cleavage fragments.
Immunoprecipitation: 1:50-1:200
Immunohistochemistry (Paraffin): 1:1000-1:5000
Optimal dilutions to be determined by the researcher.
Positive Control: Tonsil

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGSerum
SizeStorageShippingSourceHost
50ul-20CBlue IceHumanRabbit
Concentration:
Not determined
Immunogen:
Synthetic peptide corresponding to aa199-217 of the alpha and beta isoforms of human Livin (PELPTPRREVQSESAQEPG) (Alpha Accession #NP_647478, Beta Accession #NP_071444.1).
Purity:
Serum
Form
Supplied as a liquid in PBS, 0.05% sodium azide.
Specificity:
Recognizes the alpha and beta isoforms of human Livin. Will recognize other isoforms that contain the peptide immunogen sequence. Species Crossreactivity: mouse, rat
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Ma L, Y Huang, Z Song, S Feng, X Tiang, W Du, X Qui, K Heese, M Wu. 2006. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differentiation. doi:10.1038/sj.cdd4401959. 2. Crnkovic-Mertens, J Semzow, F Hoppe-Seyler K Butz. 2006. J Mol Med 84:232-240. 3. Wright CW CS Duckett. 2005. J Clin Investigation. 115:2673-2678. 4. Nachmias B, Y Ashhab, V Bucholtz, O Drize, L Kadouri, M Lotem, T Peretz, O Mendelboim, D Ben-Yehuda. 2003. Cancer Res 63:6340-6349.